Innovative RNA-Based Technology; First-in-Class Therapeutics

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta’s unique technology has yielded a diverse pipeline of RNA-based therapeutics that include our lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases.

Our exceptional science- and commercialization-focused team is committed to realizing our vision of becoming a leading, independent biotechnology company dedicated to translating our RNA-based science into transformational therapeutics and, most importantly, bringing these novel therapeutics to patients who have no other options.